A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do more than produce a nice image on a slide. On the figures disclosed, the Cardiovalve TR System has made a credible case that it can.
Durability Is the Part That Gets Attention
TARGET enrolled 157 symptomatic patients with at least severe tricuspid regurgitation, with 148 receiving an implant. Their mean age was 78, 71% were women, 99% had secondary TR, and nearly 40% had torrential TR. This was no easy-patient parade. These were high-risk open-heart-surgery candidates, which makes both the clinical need and the safety bar painfully real.
The study met its 30-day performance endpoint: successful implantation with TR reduced to 2+ or less. More importantly, Venus says the reduction held up through three years, with 76.9% of patients reaching none or trace TR at that point. In structural-heart devices, durability is where plenty of early enthusiasm goes to die. A three-year signal is not a final verdict, but it is a lot more useful than a 30-day victory lap.
Patients Seem to Feel the Difference
The functional measures line up with the imaging outcome. At one year, the six-minute walk test improved by an average of 42 meters, while the Kansas City Cardiomyopathy Questionnaire score improved by 20 points. By three years, 80% of patients were classified as NYHA I or II, versus 39.9% at baseline. The company also reported reverse right-heart remodeling, including reductions in inferior vena cava diameter of 25%, mid-right-ventricular end-diastolic diameter of 22%, and basal RVEDD of 11%.
Those are encouraging readings because a device that merely alters a valve grade without helping a frail patient walk farther or function better has a commercial problem, plain and simple. Still, sensible observers should remember what TARGET is: a multicenter, prospective, single-arm, open-label study. There is no randomized control group in the disclosed material. The results deserve respect, not blind extrapolation against other therapies.
- The three-year none-or-trace TR result is the headline durability figure.
- The 42-meter walk improvement and 20-point KCCQ gain provide patient-centered support.
- The lack of a stated comparator means relative performance remains an open question.
The Delivery-System Improvement May Matter Most
Safety is where this story turns from promising to genuinely worth watching. TARGET met its 30-day composite major-adverse-event endpoint under TVARC definitions. At 30 days, all-cause mortality was 5.7%, heart-failure rehospitalization was 1.9%, and major access-site or vascular injury requiring surgery was 5.1%. Nobody should toss those numbers around casually; this is a severely ill, high-risk group, and mortality is not a footnote.
What caught my eye was the comparison between delivery-system generations. With the Enhanced Delivery System, major bleeding was reported at 5.0%, down from 21% with the first-generation system. Major vascular complications declined to 3.0% from 8.8%. Device therapies often get their reputation made or broken by the delivery hardware. If those improvements persist as use expands, they could make the procedure more practical for physicians and less punishing for patients.
Approval Is Still a Milestone, Not a Revenue Line
For investors following Venus Medtech, 2500.HK, the next event is regulatory rather than clinical. Cardiovalve is preparing its CE Mark application, and the company expects potential European commercialization in the second half of 2027. That wording is appropriately squishy. Potential is not approval, and approval is not uptake. Hospitals, physician training, reimbursement, manufacturing capacity and competition all get their say after regulators do.
Still, Venus has a broader structural-heart pipeline across all four valves, and Cardiovalve brings more than 150 approved patents into that setup. TARGET does not settle the competitive debate in transcatheter tricuspid replacement. It does give the company a more substantial clinical foundation than a one-year snapshot ever could. The next useful proof will be regulatory progress and evidence that these results travel cleanly from a study cohort into ordinary clinical practice.